slides · global inventory
Solution
Slide type collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 8,880
Current window 6,181-6,210
Pages 296
Rows per page 30
Slide type
6,181-6,210 of 8,880
07
The slide uses a hub-and-spoke style diagram to categorize mathematical problem types into three buckets, then maps them to quantum computing modalities.D-Wave | Investor Presentation Deck | 28 slides · D-Wave
Pitch deck Investor relations Beat · InterestLoop · Logic Chain1 hit
22
Uses a Venn diagram to illustrate the three pillars of quantum system performance.D-Wave | Investor Presentation Deck | 28 slides · D-Wave
Pitch deck Investor relations Beat · ActionLoop · Cost Of Inaction1 hit
24
D-Wave | Investor Presentation Deck | 28 slidesD-Wave | Investor Presentation Deck | 28 slides · D-Wave
Pitch deck Investor relations Beat · Action1 hit
11
The slide uses a numbered diagram to map components to the table.Eos Energy | Investor Presentation Deck | 24 slides · Eos Energy Enterprises
Pitch deck Investor relations Beat · Solution & ApproachLoop · Quick Win Big Bet1 hit
13
Uses a combination of SEM imagery for material changes and diagrams for structural/systemic improvements.Eos Energy | Investor Presentation Deck | 24 slides · Eos Energy Enterprises
Pitch deck Investor relations Beat · Solution & ApproachLoop · Quick Win Big Bet1 hit
14
The slide uses a combination of technical diagrams and benefit-driven bullet points to highlight the value proposition of the Z3 product.Eos Energy | Investor Presentation Deck | 24 slides · Eos Energy Enterprises
Pitch deck Investor relations Beat · Solution & ApproachLoop · Quick Win Big Bet1 hit
05
This is a section divider or introductory slide for the product solution.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
11
The diagram uses a hub-and-spoke model to show how various scientific disciplines feed into the central 'Drug Products' core.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
12
The slide highlights the structural commonality of the γC receptor across multiple cytokines, positioning it as a therapeutic target.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
13
The slide uses a structural biology approach to explain the mechanism of action for their therapeutic platform.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
14
The slide uses a biological process diagram to illustrate how the inhibitor prevents the dimerization of private receptors with the shared receptor.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
17
The slide uses a four-column structure to explain the target, molecular nature, preclinical results, and clinical status.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
19
The slide uses Western blot data to visually demonstrate the efficacy of EQ101 compared to a standard JAK inhibitor.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
22
The slide uses a circular process diagram to show the feedback loop of cytokines and immune cells leading to hair loss.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
06
Uses a process diagram to show the transition from cold to hot tumor states.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Beat · Solution1 hit
07
The central diagram illustrates the mechanism of action, contrasting 'Absence of Effector T Cells' (Platinum resistant) with 'Presence of Effector T Cells' (Platinum sensitive).Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Beat · Solution1 hit
21
The slide highlights the synergy between two distinct therapeutic approaches (oncolytic immunotherapy and adoptive cell therapy).Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
37
The slide uses clinical data (cytokine levels and PD-L1 staining) to support the mechanism of action.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
05
The slide uses a causal-chain framework to link platform capabilities to strategic outcomes.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Situation & Context1 hit
06
Includes a B-cell development diagram and a human anatomy map linking specific diseases to medical specialties.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Problem & Complication1 hit
08
The slide uses a structural diagram to highlight the substitution of the 'Tumor Binding Domain' with the 'COBRA Binder' in the NXC-201 molecule.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Problem & Complication1 hit
09
The slide uses a diagram to map specific protein domains to their functional benefits.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Problem & Complication1 hit
10
The slide uses external citations from Nature Medicine and Signal Transduction and Targeted Therapy to validate the scientific approach of ITAM modification.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Problem & Complication1 hit
12
Includes a scientific quote justifying the use of Glycine/Serine linkers.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Problem & Complication1 hit
13
The slide uses a hub-and-spoke diagram to highlight four key clinical outcomes.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Problem & Complication1 hit
16
Includes comparative data points for transduction efficiency and experimental data for tonic signaling and anti-exhaustion.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & Proof1 hit
36
Includes a complex biological pathway diagram and three supporting charts (penetration depth, accumulation over time, and apoptosis efficacy).Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
54
Includes comparative size illustration of IMX-111 vs IgG antibody, and survival curve data.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
56
The slide uses a mix of mechanism-of-action diagrams, clinical trial bar charts, and preclinical mouse model data to validate the therapeutic approach.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
58
The slide uses a side-by-side comparison structure to explain two distinct but complementary proprietary platforms.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit